The sensory-reactivity PROM set: identification of a parent reported outcome measure set for autism spectrum disorder

Autor: Dorinde M. van Andel, Henk F. van Stel, Floortje E. Scheepers, Kim J. Oostrom, Lotte Haverman, Hilgo Bruining

Publikováno v: Journal of Patient-Reported Outcomes, Vol 5, Iss 1, Pp 1-7 (2021)

Abstract Background Most children with autism spectrum disorder (ASD) suffer from aberrant responses to sensory stimuli that significantly impact the quality of life. To develop sensory interventions, individually tailored outcome measures are crucia

Externí odkaz: https://doaj.org/article/1e3a5da8965644c8b7f6fe3785dd8b1c

Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot study

Autor: Dorinde M. van Andel, Jan J. Sprengers, Bob Oranje, Floortje E. Scheepers, Floor E. Jansen, Hilgo Bruining

Publikováno v: Molecular Autism, Vol 11, Iss 1, Pp 1-14 (2020)

Abstract Background Tuberous sclerosis complex (TSC) is an autosomal dominant disease that affects multiple organs including the brain. TSC is strongly associated with broad neurodevelopmental disorders, including autism spectrum disorder symptomatol

Externí odkaz: https://doaj.org/article/6e21336f0ad548a5a001ea4b67b61b60

Effects of Bumetanide on Neurocognitive Functioning in Children with Autism Spectrum Disorder

Autor: Dorinde M van Andel, Jan J Sprengers, Marsh Königs, Maretha V de Jonge, Hilgo Bruining

Publikováno v: Journal of Autism and Developmental Disorders. Springer New York
Journal of autism and developmental disorders. Springer New York
van Andel, D M, Sprengers, J J, Königs, M, de Jonge, M V & Bruining, H 2023, ' Effects of Bumetanide on Neurocognitive Functioning in Children with Autism Spectrum Disorder : Secondary Analysis of a Randomized Placebo-Controlled Trial ', Journal of Autism and Developmental Disorders . https://doi.org/10.1007/s10803-022-05841-3

We present the secondary-analysis of neurocognitive tests in the ‘Bumetanide in Autism Medication and Biomarker’ (BAMBI;EUDRA-CT-2014-001560-35) study, a randomized double-blind placebo-controlled (1:1) trial testing 3-months bumetanide treatment

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba6ddd19f375f64c946ec45819de0848
http://www.scopus.com/inward/record.url?scp=85145889834&partnerID=8YFLogxK

Bumetanide for Irritability in Children With Sensory Processing Problems Across Neurodevelopmental Disorders:A Pilot Randomized Controlled Trial

Autor: Dorinde M. van Andel, Jan J. Sprengers, Mandy G. Keijzer-Veen, Annelien J. A. Schulp, Marc R. Lillien, Floortje E. Scheepers, Hilgo Bruining

Publikováno v: van Andel, D M, Sprengers, J J, Keijzer-Veen, M G, Schulp, A J A, Lillien, M R, Scheepers, F E & Bruining, H 2022, ' Bumetanide for Irritability in Children With Sensory Processing Problems Across Neurodevelopmental Disorders : A Pilot Randomized Controlled Trial ', Frontiers in Psychiatry, vol. 13, 780281 . https://doi.org/10.3389/fpsyt.2022.780281
Frontiers in Psychiatry, 13:780281. Frontiers Media S.A.
Frontiers in Psychiatry, Vol 13 (2022)
Frontiers in psychiatry, 13:780281. Frontiers Media S.A.

BackgroundTreatment development for neurodevelopmental disorders (NDDs) such as autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) is impeded by heterogeneity in clinical manifestation and underlying etiologies. Sympto

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e69b2d400dd5163f7492fe79f11be11d
https://research.vumc.nl/en/publications/978d81bd-7d0c-4b0f-88ae-0f98cf0de4ee

Prediction of Behavioral Improvement Through Resting-State Electroencephalography and Clinical Severity in a Randomized Controlled Trial Testing Bumetanide in Autism Spectrum Disorder

Autor: Bob Oranje, Jan J. Sprengers, Gianina Cristian, Klaus Linkenkaer-Hansen, Sonja Simpraga, Huibert D. Mansvelder, Simon J. Houtman, Gert Jan van der Wilt, Erika Juarez-Martinez, Richard Hardstone, Hilgo Bruining, Cathalijn Gerver, Marinus J.C. Eijkemans, Arthur Ervin Avramiea, Dorinde M. van Andel

Publikováno v: Biological Psychiatry : Cognitive Neuroscience and Neuroimaging, 8(3), 251-261. Elsevier
Juarez-Martinez, E L, Sprengers, J J, Cristian, G, Oranje, B, van Andel, D M, Avramiea, A E, Simpraga, S, Houtman, S J, Hardstone, R, Gerver, C, Jan van der Wilt, G, Mansvelder, H D, Eijkemans, M J C, Linkenkaer-Hansen, K & Bruining, H 2021, ' Prediction of Behavioral Improvement Through Resting-State Electroencephalography and Clinical Severity in a Randomized Controlled Trial Testing Bumetanide in Autism Spectrum Disorder ', Biological Psychiatry: Cognitive Neuroscience and Neuroimaging . https://doi.org/10.1016/j.bpsc.2021.08.009
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging. Elsevier Inc.
Biological Psychiatry : Cognitive Neuroscience and Neuroimaging, 8, 251-261
Juarez-Martinez, E L, Sprengers, J J, Cristian, G, Oranje, B, van Andel, D M, Avramiea, A-E, Simpraga, S, Houtman, S J, Hardstone, R, Gerver, C, Jan van der Wilt, G, Mansvelder, H D, Eijkemans, M J C, Linkenkaer-Hansen, K & Bruining, H 2021, ' Prediction of Behavioral Improvement Through Resting-State Electroencephalography and Clinical Severity in a Randomized Controlled Trial Testing Bumetanide in Autism Spectrum Disorder ', Biological Psychiatry : Cognitive Neuroscience and Neuroimaging, vol. 8, no. 3, pp. 251-261 . https://doi.org/10.1016/j.bpsc.2021.08.009
Biological Psychiatry : Cognitive Neuroscience and Neuroimaging, 8, 3, pp. 251-261

Item does not contain fulltext BACKGROUND: Mechanism-based treatments such as bumetanide are being repurposed for autism spectrum disorder. We recently reported beneficial effects on repetitive behavioral symptoms that might be related to regulating

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ee9d6cc74a8a3e5b4c373ed5190f0ce
https://doi.org/10.1016/j.bpsc.2021.08.009